Loading
A phase 1 trial of NG-350A run by Akamis Bio, active, not recruiting.
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer is a phase 1 interventional study registered as NCT06459869 by Akamis Bio, with 33 participants planned, started 2025-04-07, primary completion expected 2027-01-30. Conditions recorded: Locally Advanced Rectal Cancer (LARC). Interventions recorded: NG-350A IV administration, Capecitabine oral administration, Radiotherapy.
Shares NG-350A, Akamis Bio and the tag pipeline.
Shares NG-350A, Akamis Bio and the tag pipeline.
Shares Akamis Bio and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/